MeSH term
Frequency | Condition_Probility | Adult | 28 | 0.0 |
Female | 49 | 0.0 |
Glutathione Transferase/*genetics | 43 | 6.0 |
Humans | 70 | 0.0 |
Male | 50 | 0.0 |
*Polymorphism, Genetic | 19 | 0.0 |
Research Support, Non-U.S. Gov't | 50 | 0.0 |
Risk Factors | 23 | 0.0 |
Smoking/adverse effects | 6 | 2.0 |
Ultraviolet Rays/adverse effects | 2 | 3.0 |
Carcinoma, Squamous Cell/*genetics/mortality/pathology | 2 | 14.0 |
Cytochrome P-450 Enzyme System/*genetics | 9 | 2.0 |
Disease-Free Survival | 2 | 0.0 |
English Abstract | 4 | 0.0 |
Follow-Up Studies | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/physiology | 2 | 1.0 |
Genotype | 39 | 0.0 |
Polymorphism, Genetic/*genetics | 7 | 0.0 |
Prognosis | 4 | 0.0 |
Survival Rate | 2 | 0.0 |
Case-Control Studies | 13 | 0.0 |
*Genetic Predisposition to Disease | 6 | 0.0 |
India | 2 | 0.0 |
Isoenzymes/*genetics | 8 | 1.0 |
Smoking | 6 | 1.0 |
Tobacco | 2 | 7.0 |
Asthma/*chemically induced/genetics | 2 | 100.0 |
Comparative Study | 13 | 0.0 |
Genetic Predisposition to Disease | 11 | 0.0 |
Glutathione Transferase/genetics | 5 | 1.0 |
Isocyanates/*adverse effects | 2 | 66.0 |
Odds Ratio | 7 | 0.0 |
Gene Expression Regulation, Enzymologic | 5 | 0.0 |
Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Lung Neoplasms/enzymology/*genetics | 2 | 5.0 |
Middle Aged | 39 | 0.0 |
Multivariate Analysis | 4 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 9 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Aged | 27 | 0.0 |
Aged, 80 and over | 8 | 0.0 |
Gene Frequency | 11 | 0.0 |
Isoenzymes/genetics | 9 | 2.0 |
Polymerase Chain Reaction | 12 | 0.0 |
Polymorphism, Genetic | 7 | 0.0 |
Glutathione Transferase/genetics/metabolism | 2 | 1.0 |
Genetics, Population | 2 | 0.0 |
Adolescent | 6 | 0.0 |
Age Factors | 3 | 0.0 |
Child | 4 | 0.0 |
Child, Preschool | 3 | 0.0 |
Exons | 2 | 0.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Homozygote | 4 | 0.0 |
Infant | 2 | 0.0 |
Oxidative Stress/genetics | 2 | 8.0 |
Reference Values | 4 | 0.0 |
Gene Deletion | 2 | 0.0 |
Carcinoma, Basal Cell/*genetics | 2 | 14.0 |
Phenotype | 4 | 0.0 |
Skin Neoplasms/*genetics | 2 | 1.0 |
Base Sequence | 8 | 0.0 |
DNA Primers | 4 | 0.0 |
DNA, Neoplasm/genetics | 2 | 0.0 |
Variation (Genetics)/*genetics | 2 | 0.0 |
Alleles | 9 | 0.0 |
Genetic Predisposition to Disease/*genetics | 2 | 0.0 |
Heterozygote | 3 | 0.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Chi-Square Distribution | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Amino Acid Sequence | 3 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Cytosol/enzymology | 4 | 2.0 |
Substrate Specificity | 2 | 0.0 |
Mouth Neoplasms/*genetics | 2 | 4.0 |
United States | 2 | 0.0 |
Analysis of Variance | 2 | 0.0 |
Cell Line | 3 | 0.0 |
Sex Factors | 4 | 0.0 |
Epoxide Hydrolases/*genetics | 2 | 6.0 |
Alcohol Drinking/adverse effects | 4 | 8.0 |
Carcinoma, Basal Cell/enzymology/*genetics | 2 | 40.0 |
Skin Neoplasms/enzymology/*genetics | 2 | 25.0 |
Regression Analysis | 3 | 0.0 |
Confidence Intervals | 2 | 0.0 |
Laryngeal Neoplasms/*genetics | 3 | 17.0 |
Logistic Models | 3 | 0.0 |
Immunohistochemistry | 5 | 0.0 |
Smoking/*adverse effects | 3 | 1.0 |
Glutathione Transferase/chemistry/*genetics | 2 | 16.0 |
Molecular Sequence Data | 4 | 0.0 |
Restriction Mapping | 2 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Disease Susceptibility | 2 | 0.0 |
Lung/*enzymology | 3 | 4.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Carcinoma, Squamous Cell/enzymology/*genetics | 2 | 12.0 |
Pharyngeal Neoplasms/genetics | 2 | 28.0 |
Cytochrome P-450 CYP1A1/genetics | 4 | 4.0 |
Cytochrome P-450 CYP2D6/genetics | 3 | 9.0 |
Cytochrome P-450 CYP2E1/genetics | 2 | 5.0 |
Protein Conformation | 2 | 0.0 |
Cohort Studies | 2 | 0.0 |
Organ Specificity | 2 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
Carcinoma, Squamous Cell/*genetics | 2 | 1.0 |
Software | 2 | 0.0 |
Glutathione Transferase/*metabolism | 2 | 6.0 |
*Chromosomes, Human, Pair 1 | 2 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Blotting, Western | 2 | 0.0 |
